Acasti Pharma Inc (CVE:ACST) shares traded up 2.8% on Tuesday . The stock traded as high as C$2.58 and last traded at C$2.55, 80,809 shares traded hands during mid-day trading. A decline of 20% from the average session volume of 101,032 shares. The stock had previously closed at C$2.48.
The company has a quick ratio of 1.76, a current ratio of 1.81 and a debt-to-equity ratio of 52.34. The stock’s 50 day moving average is C$2.65 and its 200-day moving average is C$2.27. The company has a market cap of $215.02 million and a PE ratio of -3.18.
Acasti Pharma Company Profile (CVE:ACST)
Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.
Read More: SEC Filing
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.